Drugs / Zampilimab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04705350 | Jan → Jul 2021 | — | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04335578 | Oct 2019 → May 2022 | chronic transplant rejection | UCB Biopharma SRL | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zampilimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04705350 ↗ |
| Route | Intravenous | “Participants will receive a single intravenous dose of zampilimab at a pre-specified time point.” NCT04705350 ↗ |